These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16517236)

  • 1. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
    Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
    Cwikla JB; Sankowski A; Seklecka N; Buscombe JR; Nasierowska-Guttmejer A; Jeziorski KG; Mikolajczak R; Pawlak D; Stepien K; Walecki J
    Ann Oncol; 2010 Apr; 21(4):787-794. PubMed ID: 19833821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
    Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
    J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
    Savelli G; Bertagna F; Franco F; Dognini L; Bosio G; Migliorati E; Rodella C; Biasiotto G; Bettinsoli G; Minari C; Zaniboni A; Ferrari C; Tomassetti P; Ferrari V; Giubbini R
    Cancer; 2012 Jun; 118(11):2915-24. PubMed ID: 22020784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
    Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
    Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 15. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
    Forrer F; Waldherr C; Maecke HR; Mueller-Brand J
    Anticancer Res; 2006; 26(1B):703-7. PubMed ID: 16739341
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Das S; Al-Toubah T; El-Haddad G; Strosberg J
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
    [No Abstract]   [Full Text] [Related]  

  • 20. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.
    Imhof A; Brunner P; Marincek N; Briel M; Schindler C; Rasch H; Mäcke HR; Rochlitz C; Müller-Brand J; Walter MA
    J Clin Oncol; 2011 Jun; 29(17):2416-23. PubMed ID: 21555692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.